CS Paper Radar

SpecOpt: Contact-Diff Reasoning for Agentic Molecule Optimization Toward Binding Specificity

Thao Nguyen, Heng Ji

cs.AI ·submitted 2026-09-18 00:16 UTC · v1
benchmark

Abstract

Off-target protein binding is a major source of adverse effects for small-molecule drugs, yet most structure-based molecular design methods focus on generating selective compounds de novo rather than improving the selectivity of existing, well- characterized drugs. We introduce specificity optimization (SpecOpt), a molecular design task that seeks constrained structural modifications to an existing compound that increase its binding preference for an intended target over known off-targets while preserving its structural identity and drug-like properties. To enable systematic evaluation, we construct a ChEMBL-derived benchmark from compound-target interaction data, identifying intended targets through curated drug-mechanism annotations and off- targets through measured activities. We then develop an agentic framework that docks each compound against its intended target and off-targets, compares the resulting poses through residue-aware atom-protein contacts, and provides these differential interactions to a large language model to propose targeted structural modifications. Candidates are retained only if they satisfy molecular similarity, ADMET, and target-off-target docking selectivity criteria. On 915 compounds, the agent improves the target- off-target binding gap for 84.8% of compounds, shifting the mean gap from -0.72 to +0.47 kcal/mol while maintaining a mean Tanimoto similarity of 0.72 to the starting compounds. Ablation studies identify residue-specific contact information as the critical optimization signal: replacing residue identities with binary contact indicators eliminates improvement on all 29 ablation compounds. These results establish SpecOpt as a distinct molecular design problem and demonstrate residue-aware differential interactions as an effective signal for improving the specificity of existing compounds.

Closest papers

Nearest neighbours by meaning across the whole index.

On the Selectivity of Generative Models in Structure-Based Drug Design

cs.LG cs.AI ·2026-10-16 ·Ella Miray Rajaonson, Jungyoon Lee, William Chau, Alan Aspuru-Guzik, Benjamin Sanchez-Lengeling +3 more
top venuebenchmarkcode/data similarity 0.72
Abstract · Accepted as a Presentation at the Neural Information Processing Systems 2026

Designing small-molecule drugs that selectively bind to a target protein while avoiding unintended interactions with other proteins is essential for reducing side effects that contribute substantially to clinical attrition. Although structure-based drug design (SBDD) has advanced rapidly with deep learning, most generative models still optimize binding to a single target and disregard selectivity due to limited training data and unknown off-target interactions. Motivated by this gap, we introduce SELECTBENCH, a comprehensive benchmark assessing the selectivity of generative SBDD models. SELECTBENCH provides three curated evaluation tasks reflecting different real-world drug discovery scenarios: literature-based case studies, safety screening panels used in pharmaceutical development, and large-scale structure-based evaluation sets. We further introduce a suite of metrics to quantify selectivity and conduct a systematic evaluation of nine representative SBDD models, including methods explicitly trained for selectivity and widely-used inference-time guidance techniques. Our results show that even selectivity-trained models achieve only modest off-target discrimination and inference-time guidance provides limited gains, underscoring the need for method improvement. SELECTBENCH provides both a characterization of where current generative SBDD stands on selectivity and an open, extensible platform to accelerate progress. The benchmark is available at https://github.com/lovetaro/selectbench.

0.44

ProbeMatchDTI: Probe-Driven Multi-Scale Biochemical Pattern Matching for Drug-Target Interaction Prediction

cs.LG cs.AI ·2026-09-02 ·Quan Hao, Mengyue Fan, Zifan Dong, Youru Li, Jianduo Zhao +6 more
code/data similarity 0.72
Abstract

Drug-target interaction (DTI) prediction is an important task in AI-driven drug discovery. Although recent biochemical representation learning methods have improved DTI prediction, their passive feature aggregation tends to favor dominant molecular patterns while suppressing weak yet binding-relevant signals, such as functional groups and residue-context patterns, limiting the modeling of multi-scale biochemical correspondences. To address this issue, we propose ProbeMatchDTI, a pattern-probe-driven framework comprising IterProbe and BindingProbe. IterProbe explicitly retains contextual states across refinement depths and uses learnable probes to select them at each position before cross-entity matching, thereby preserving weak biochemical patterns and strengthening associations among functional groups, local motifs, and molecular scaffolds. BindingProbe then characterizes cross-entity drug-protein complementarity at local biochemical-unit and whole-pair levels, jointly modeling fine-grained interactions and multi-scale correspondences while preserving weaker binding-relevant associations. Extensive experiments demonstrate the superiority of ProbeMatchDTI, achieving 2.0% and 0.5% higher AUC-ROC on BindingDB and DrugBank, respectively. Feature-level pattern analyses further characterize its probe-driven behavior in cross-scale biochemical pattern matching. We further connect ProbeMatchDTI predictions with an evidence-guided downstream drug-discovery workflow, demonstrating their utility for candidate refinement and validation planning. Our code is available at https://github.com/developer-hq/ProbeMatchDTI

0.28

Chemical and geometric representation fidelity improves drug--target affinity prediction

cs.AI q-bio.BMcs.LGstat.ML ·2026-09-02 ·Yixiao Li, Yining Qian, Yefan Chen, Zenghui Chen, Jiayue Sun +3 more
benchmark similarity 0.71
Abstract · 21 pages, 10 figures

Predicting drug--target binding affinity (DTA) requires models to distinguish subtle chemical and structural determinants underlying molecular recognition. Although recent approaches increasingly incorporate richer drug and protein information, such information may be compressed, homogenized or discretized during representation construction, causing affinity-relevant distinctions to be lost before interaction modelling. We hypothesized that this representation-stage information loss constitutes an upstream bottleneck that cannot be reliably overcome by increasingly complex interaction predictors. To test this hypothesis, we developed ReGeoDTA, a representation-preserving framework that maintains affinity-relevant chemical heterogeneity in molecular representations and continuous geometric relationships in protein structures. Across three benchmark datasets, ReGeoDTA consistently improved affinity prediction, and the proposed representation-preserving strategies retained their benefits across diverse DTA architectures. Controlled representation degradation progressively reduced predictive performance, whereas increasing downstream predictor complexity failed to recover information lost during representation construction. These findings identify representation fidelity as an upstream design principle for accurate and generalizable drug--target affinity prediction, with potential implications for computational compound prioritization.

0.23

HierDTA: Hierarchical Structure-Aware Representation Learning for Drug--Target Affinity Prediction

cs.LG cs.AI ·2026-10-19 ·Huangchao Xu, Baohua Zhang, Qian Liu, Zhong Jin, Yi Du
published similarity 0.71
Abstract · 20 pages, 7 figures

Drug--target affinity (DTA) prediction plays an important role in computer-aided drug discovery, where reliable computational models can help prioritize compound--protein pairs before experimental validation. A key challenge in DTA prediction is to effectively mine multi-level molecular information from drug structures while accurately modeling the binding-site environment of target proteins. To address these issues, we introduce HierDTA, a hierarchical structure-aware framework for DTA prediction. \textcolor{black}{HierDTA represents each drug as an atom--motif heterogeneous graph and introduces an augmentation module that propagates functional-motif semantics to the corresponding atoms. For proteins, kinase-domain structures are converted into residue interaction graphs. The resulting atom and residue representations are integrated using cross-attention to capture pair-specific relationships, while molecule fingerprints and pretrained ESM-2 embeddings provide complementary global information. Compared with state-of-the-art methods, HierDTA achieves superior performance on the Davis dataset across all metrics and attains the highest \(r_m^2\) of 0.791 on KIBA. It also exhibits strong generalization under cold-start settings, particularly on KIBA, where MSE is reduced by 21.7\% in the unseen-protein scenario. Ablation study and interpretability analysis supported the contributions of the hierarchical augmentation and interaction components.} Case studies further showed that HierDTA provided early enrichment of candidate bioactive compounds. These results indicate that HierDTA is an effective framework for affinity prediction and target-specific virtual screening.

0.31

SurfSpec: Enhancing Off-Target-Agnostic Specificity by Bounding Pocket-Ligand Geometric Mismatch

cs.LG q-bio.QM ·2026-09-02 ·Minyeong Hwang, Yoorim Gang, Ziseok Lee, Wooyeol Lee, Young Bin Park +3 more
theoryhot direction similarity 0.70
Abstract

Lead optimization in structure-based drug design aims to improve target binding while avoiding unintended interactions with off-target pockets. However, existing affinity-driven methods do not explicitly control specificity, whereas current specificity-aware approaches commonly require prior knowledge of off-target structures. We address off-target-agnostic specificity-aware lead optimization by analyzing the geometric mismatch between a ligand and the target pocket. We provide a conservative specificity lower bound for geometrically separated off-targets without requiring access to off-target structures. By metricizing pocket--ligand mismatch, the triangle inequality shows that reducing target--ligand mismatch improves a conservative lower bound on mismatch to a separated off-target class, which can be translated into a specificity lower bound through an empirical geometry--affinity calibration. Motivated by this analysis, we introduce SurfSpec, an off-target-agnostic lead optimization framework that iteratively grows ligands toward under-occupied regions of the target pocket surface. SurfSpec alternates between linker generation toward selected target-surface patches, which provides geometric pseudo-labels, and refinement under a pocket-conditioned ligand prior, which restores these pseudo-labels into valid ligands. On the CrossDocked2020 test set, SurfSpec reduces geometric mismatch and outperforms evaluated off-target-agnostic lead optimization baselines in empirical specificity, while maintaining competitive target-affinity improvement.

0.30

Binding Mode Matters: Hotspot-Aware Drug Discovery via Explorative Preferences

cs.LG cs.AI ·2026-11-11 ·Dingshuo Chen, Hao Yang, Kuangqi Zhou, Zhixun Li, Qiang Liu +3 more
top venue similarity 0.70
Abstract · To appear at NeurIPS 2026, 26 pages

Discovering hit molecules requires not just high binding affinity, but also the identification of diverse binding modes, which are critical for experimental assays. Existing generative approaches have predominantly relied on optimizing a scalar docking score, obscuring the distinct contributions of key binding determinants. To this end, we introduce a paradigm shift by formulating target-based drug design as a multi-objective exploration task, where each objective explicitly corresponds to enhancing interactions with a specific hotspot. Here, we introduce BindMol, a novel generative framework driven by a customized multi-objective reinforcement learning algorithm. By incorporating explorative preferences during training, our approach efficiently uncovers molecules with diverse and desirable binding profiles. Empirical results demonstrate that BindMol facilitates the discovery of high-affinity compounds characterized by both structural novelty and diverse binding modes. Validated across target-based drug discovery and multi-property optimization tasks, our approach provides a versatile paradigm for goal-oriented drug discovery.

0.45

PMO-Dock: Benchmarking Docking, Specificity, and Generalization in Molecular Optimization

cs.LG q-bio.QM ·2026-10-13 ·Gor Simonyan, Tatevik Abrahamyan, Narek Abelyan, Tigran Fahradyan, Hrant Khachatrian
benchmark similarity 0.69
Abstract

The Practical Molecular Optimization (PMO) benchmark standardized evaluation in molecular optimization, but it is built on simple property-based oracles that do not capture structure-based drug design. As the field has moved to docking-based objectives, evaluation practice has become unstandardized, and different methods report results on different docking tasks, often without a shared protocol for fair comparison or sample-efficiency constraints. To address this, we introduce Practical Molecular Optimization for Docking (PMO-Dock), a benchmark and protocol for docking-based optimization consisting of 25 tasks covering hit generation, lead optimization, and a new specificity task requiring strong on-target binding while penalizing off-target interactions. The protocol separates model development from final evaluation: validation tasks are used for hyperparameter tuning, and test tasks are held out for final evaluation and are not used during development. Evaluation on the test tasks is done under a strict oracle budget to reflect realistic drug-discovery settings. We benchmark four diverse high-performing methods spanning different optimization paradigms, Saturn (reinforcement learning), GenMol (discrete diffusion), Genetic-guided GFlowNet, and ChemLlama (LLM-based evolutionary search). Our results show no universally best method across tasks, additional analyses of hyperparameter transfer (cross-task and cross-category) and sensitivity show that transfer is often limited and varies by method, motivating method-dependent selection strategies. This benchmark provides a concrete standard for evaluating generalization to unseen tasks and sample efficiency under a limited test-time oracle budget.

0.18

MolHop: Scaffold-Hopping Molecular Design with Agentic Reinforcement Learning

cs.LG cs.CL ·2026-10-14 ·Yanyi Su, Chenyan Wang, Yulei Gong, Yeyun Chen, Xiaohui Yang +1 more
similarity 0.69
Abstract · Under review at ICLR 2027

Molecular design is often formulated as an optimization problem over existing molecular spaces. However, molecular optimization and the discovery of structurally distinct replacement molecules represent two fundamentally different search problems. LLM-based molecular design agents typically perform the former, conducting local refinement within the neighborhood of existing structures to improve target properties through structural modifications. In contrast, the latter requires exploration of a broader chemical space to discover molecules with entirely different scaffolds while preserving the functional characteristics of reference molecules. We propose MolHop, an agentic framework for cross-scaffold molecular discovery that enables models to navigate and edit within a pre-organized chemical space. MolHop organizes approximately 1.6 million molecular scaffolds from commercial molecules into a coarse-to-fine hierarchical action space. The agent selects new exploration regions through scaffold navigation actions and adjusts candidate properties through molecular editing. The framework maintains historical trajectory memory to support long-horizon search processes. On drug molecule and commercial compound tasks, connecting Grok-4.6 and DeepSeek-Flash-V4.1 to the MolHop framework substantially improves their cross-scaffold joint success rates. We develop MolHop-9B through agentic reinforcement learning, and MolHop-9B outperforms generative baselines including GPT-5.6-sol, Claude-5-Opus, and Gemini-3.1-Pro, while generating candidate molecules with larger scaffold differences from the reference molecules. These results demonstrate that effective molecular discovery beyond the traditional optimization paradigm requires structured chemical and action spaces, enabling agents to explore new structural regions rather than merely refine existing molecules.

0.19